

RedHill Announces Transformational Acquisition of Commercialization Rights to Ferring's Rebyota® and Clenpiq®

Creates a catalyst for growth through a larger GI business, with a significantly stronger liquidity position and provides additional expansion opportunities

RALEIGH, NC, UNITED STATES,
September 1, 2026 /EINPresswire.com/

-- Together with the previously announced Talicia® strategic divestiture, the acquisition from Ferring of commercialization rights to two larger, proprietary, established gastrointestinal (GI) FDA-approved drugs that together generated approximately \$37.5 million in 2025 net sales, completes a major strategic repositioning of RedHill's commercial GI business

--

The divestiture of Talicia and the acquisition of the new GI products from Ferring create a catalyst for commercial growth through a materially larger GI business under RedHill's control, with a significantly stronger liquidity position and provides additional growth and expansion opportunities

“

We have monetized Talicia for \$18 million cash upfront and \$35 million in potential upside, used \$12 million to secure rights to two FDA-approved GI drugs, that generated \$37.5 million in 2025 sales.”

Dror Ben-Asher, RedHill's Chief Executive Officer



RedHill's Transformational Acquisition of Commercialization Rights to Ferring's Rebyota® and Clenpiq®

--

Under the terms of the agreement, RedHill obtained the exclusive commercialization rights for an upfront payment to Ferring of \$12 million plus potential future milestones and tiered royalties.

The \$12 million upfront payment is fully funded through the previously announced \$18 million Talicia divestment, with RedHill securing exclusive global and U.S. commercialization rights to Ferring's Rebyota® and Clenpiq®, respectively - two synergistic, revenue-generating, FDA-approved GI drugs

--

Rebyota is a proprietary, first and only single-dose FDA-approved Fecal Microbiota Transplant (FMT for prevention of recurrent C. diff infection (rCDI). FDA-approved in 2022 and Health Canada-approved in 2025, Rebyota, was granted a Breakthrough Therapy and received Orphan Drug designations and generated approximately \$16.9 million in 2025 U.S. net sales

--

Proprietary Clenpiq, a ready-to-use (no mixing required) low-volume bowel preparation on the U.S. market, generated \$20.6 million in U.S. 2025 net sales with minimal promotion

RALEIGH, N.C., and TEL-AVIV, Israel, September 1, 2026 -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced the transformational acquisition of exclusive global and U.S. commercialization rights to Rebyota and Clenpiq, from Ferring Pharmaceuticals ("Ferring"), as part of Ferring's ongoing strategic refocusing.

Dror Ben-Asher, RedHill's Chief Executive Officer, said: "We have executed a clear strategic sequence. We have monetized Talicia for \$18 million cash upfront, plus \$35 million in potential upside, used \$12 million to secure commercialization rights to two established, proprietary, FDA-approved gastrointestinal drugs, that collectively generated approximately \$37.5 million in U.S. net sales in 2025, and emerged with a materially larger, fully controlled commercial business and a stronger liquidity position. Rebyota and Clenpiq are expected to generate a positive cash contribution to RedHill. This, combined with RedHill's experienced and lean commercial team and proven development capabilities, creates a scalable foundation for further growth, including additional acquisition of complementary revenue-generating products." Mr. Ben-Asher added: "We thank Ferring for a smooth process to date and look forward to a successful collaboration."

Under the terms of the agreement, RedHill obtained an exclusive global commercialization license of Rebyota and an exclusive U.S. commercialization license of Clenpiq, for an upfront payment to Ferring of \$12 million, plus tiered royalties on net sales and potential milestones. Ferring retains its Rebyota manufacturing facilities, and Ferring will continue to supply Rebyota through the term of the agreement.

"Rebyota is a first-in-class microbiota-based therapy for prevention of recurrent *Clostridioides difficile* (C. diff) infection (rCDI) in individuals 18 years of age and older following antibiotic treatment for rCDI. FDA-approved in 2022, it generated approximately \$16.9 million in U.S. net sales in 2025 through its clinical profile, broad coverage and an established customer base of approximately 600 active accounts," said Rick Scruggs, RedHill's Chief Commercial Officer. "Clenpiq, a ready-to-drink low-volume bowel preparation on the U.S. market, delivered \$20.6 million in net sales in 2025, with minimal promotion. Together the two assets give RedHill a significantly stronger commercial growth engine in both the U.S. and other new territories."

C. diff (CDI) infection is a distressing and life-threatening condition – in developed countries it is the most common cause of healthcare-associated (HA) diarrhea . An estimated 3.6 million cases

of CDI occur globally each year, including approximately half a million cases in the U.S. 30,000 Americans die every year due to CDI , with a global mortality rate of 1-in-10, rising to almost 1-in-3 in high-risk settings¹. In the U.S., up to approximately 165,000 CDI cases result in one or more recurrences , indicating the need for use of prevention strategies.

Rebyota's one-time administration, which requires no fasting, bowel prep or extended treatment timeframe, has demonstrated more than a 70% success rate at preventing rCDI . An aging population and accompanying increasing hospital-acquired vulnerabilities will likely increase this need. A streamlined ordering and reimbursement process is already in place for physicians, and broad and improving U.S. payer coverage means that 93% of lives have coverage including 43% with coverage after 1st recurrence .

Rebyota, which was granted, Breakthrough Therapy and Orphan Drug designations - with exclusivities and other patent protections that could run to 2036, provides multiple growth opportunities, including recent approval in Canada. The existing approvals also provide the potential for additional approvals in other territories.

Colonoscopy is the cornerstone of GI practice, with more than 15 million colonoscopies performed in the U.S. annually . This number is rising, with follow-up needed after noninvasive screening tests that yield a positive result, an aging population, and guidelines that recommend testing at age 45 instead of age 50, contributing to an increased need for colonoscopy. Bowel preparation is not a pleasant process and is often poorly performed.

Clenpiq is a ready-to-drink low-volume bowel prep. Clenpiq is readily available to patients and has broad commercial and government payer coverage: More than 108 million lives (63%) with unrestricted (no prior approval) have commercial coverage, including 57 million (33%) with preferred position. 23m lives (41%) of Medicare Part D lives have unrestricted access to Clenpiq, including 12m (21%) lives with preferred position⁵.

RedHill was advised by Morningstar Law Group and Greenberg Traurig LLP on this transaction.

Adi Frish

RedHill Biopharma

adi@redhillbio.com

Visit us on social media:

[LinkedIn](#)

[X](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/938710753>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable

in today's world. Please see our Editorial Guidelines for more information.
© 1995-2026 Newsmatics Inc. All Right Reserved.